Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.SJerald Sadoff, Macaya Douoguih, Johan Vingerhoets et al.|New England Journal of Medicine|2022Cited by 250
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trialKarin Hardt, Jeffrey J. Stoddard, Christian Sandrock et al.|The Lancet Infectious Diseases|2022Cited by 88